Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNE1 | P15382 | 1/20 | 0.65 |
| ▸ | CCR1 | P32246 | 1/20 | 0.65 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL20885818 | 0.99 | KCNE1 (0.64) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| SCHEMBL5314622 | 0.91 | KCNE1 (0.67) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| SCHEMBL4905094 | 0.89 | KCNE1 (0.65) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| SCHEMBL13302575 | 0.89 | KCNE1 (0.55) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| SCHEMBL13041229 | 0.88 | KCNE1 (0.69) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| SCHEMBL1150537 | 0.87 | KCNE1 (0.74) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| SCHEMBL5315124 | 0.87 | KCNE1 (0.66) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| SCHEMBL18196228 | 0.86 | KCNE1 (0.53) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| SCHEMBL19306601 | 0.86 | KCNE1 (0.75) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| SCHEMBL22571819 | 0.85 | KCNE1 (0.50) | KCNE1CCR1KCNQ1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259778-B2 | Process for the preparation of raltegravir | AUROBINDO PHARMA LTD (IN) | 2019-04-16 | — | — | US | claimed |
| EP-3102565-B1 | PROCESSES FOR THE PREPARATION OF INTERMEDIATES OF RALTEGRAVIR | MYLAN LABORATORIES LTD (IN) | 2019-01-02 | — | — | EP | claimed |
| US-20170334838-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RALTEGRAVIR | AUROBINDO PHARMA LTD (IN) | 2017-11-23 | — | — | US | claimed |
| US-20170253585-A1 | PROCESSES FOR THE PREPARATION OF INTERMEDIATES OF RALTEGRAVIR | MYLAN LABORATORIES LTD (IN) | 2017-09-07 | — | — | US | claimed |
| EP-3102565-A1 | PROCESSES FOR THE PREPARATION OF INTERMEDIATES OF RALTEGRAVIR | Mylan Laboratories Ltd. (IN) | 2016-12-14 | — | — | EP | claimed |
| WO-2015114608-A1 | PROCESSES FOR THE PREPARATION OF INTERMEDIATES OF RALTEGRAVIR | MYLAN LABORATORIES LTD (IN) | 2015-08-06 | — | — | WO | claimed |
| US-11246869-B2 | Process for the preparation of Raltegravir | CAMBREX PROFARMACO MILANO S.R.L. (IT) | 2022-02-15 | — | — | US | disclosed |
| US-11246869-B2 | Process for the preparation of Raltegravir | CAMBREX PROFARMACO MILANO S.R.L. (IT) | 2022-02-15 | — | — | US | disclosed |
| EP-3472134-B1 | PROCESS FOR PREPARING COMPOUNDS USEFUL AS INTERMEDIATES FOR THE PREPARATION OF RALTEGRAVIR | PHARMATHEN SA (GR) | 2021-10-20 | — | — | EP | disclosed |
| US-20200330466-A1 | PROCESS FOR THE PREPARATION OF RALTEGRAVIR | CAMBREX PROFARMACO MILANO S.R.L. (IT) | 2020-10-22 | — | — | US | disclosed |
| EP-2586444-B1 | Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate control composition | MERCK SHARP & DOHME (US) | 2019-09-25 | — | — | EP | disclosed |
| US-10259778-B2 | Process for the preparation of raltegravir | AUROBINDO PHARMA LTD (IN) | 2019-04-16 | — | — | US | disclosed |
| US-10259778-B2 | Process for the preparation of raltegravir | AUROBINDO PHARMA LTD (IN) | 2019-04-16 | — | — | US | disclosed |
| US-7169780-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | ISTITUTE DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-01-30 | — | — | US | disclosed |
| US-7169780-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | ISTITUTE DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-01-30 | — | — | US | disclosed |
| US-7169780-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | ISTITUTE DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-01-30 | — | — | US | disclosed |
| US-20060258860-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | MSD ITALIA S.R.L. (IT) | 2006-11-16 | — | — | US | disclosed |
| WO-2006060731-A2 | USE OF ATAZANAVIR FOR IMPROVING THE PHARMACOKINETICS OF DRUGS METABOLIZED BY UGT1A1 | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| EP-1441735-B1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ANGELETTI P IST RICHERCHE BIO (IT) | 2006-02-22 | — | — | EP | disclosed |
| US-20050025774-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase | MSD ITALIA S.R.L. (IT) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334838-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RALTEGRAVIR | SAMHD1, CYP3A5, REN | KCNE1 2620/4885CCR1 1121/4885KCNQ1 2409/4885 |
| US-10259778-B2 | Process for the preparation of raltegravir | SAMHD1, CYP3A5, HPRT1 | KCNE1 2894/4885CCR1 1027/4885KCNQ1 2689/4885 |
| US-20060258860-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | IMPDH1, ASS1, REV1 | KCNE1 4152/4885CCR1 2063/4885KCNQ1 3707/4885 |
| US-20170253585-A1 | PROCESSES FOR THE PREPARATION OF INTERMEDIATES OF RALTEGRAVIR | DUT, DCK, DCTD | KCNE1 3460/4885CCR1 3861/4885KCNQ1 3640/4885 |
| US-20200330466-A1 | PROCESS FOR THE PREPARATION OF RALTEGRAVIR | SAMHD1, CYP3A4, UGT1A4 | KCNE1 3694/4885CCR1 3418/4885KCNQ1 3866/4885 |
| US-11246869-B2 | Process for the preparation of Raltegravir | SAMHD1, CYP3A4, UGT1A4 | KCNE1 3694/4885CCR1 3418/4885KCNQ1 3866/4885 |
| US-20050025774-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase | IMPDH1, CCNI, REV1 | KCNE1 3802/4885CCR1 994/4885KCNQ1 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.